Talking Techniques

Share

The ethics of whole-genome sequencing: from race and religion to science fiction

Season 2, Ep. 11

Welcome to part two of this two-part episode on whole-genome sequencing (WGS) in rare disease research and treatment. In part one we discussed the impacts the technology has had on both improving the clinical diagnosis and management of rare diseases and on drug development and basic research studies.


This episode goes beyond the technology’s capabilities and into the debates surrounding how, when and why they should be used. What needs to change for the technique to be applied equitably? And how does reality stack up against science fiction in terms of people’s perceptions of ubiquitous WGS?


To do this I speak with David Dimmock, Senior Medical Director of the Rady Children’s Institute for Genomic Medicine (CA, USA); Christine Stanley, Chief Director of Clinical Genomics, Variantyx (MA, USA); and Take Ogawa, Vice President of Sales & Marketing at Psomagen (MD, USA). Each of these speakers provides their opinions on the impacts of race, religion and way of life on the application of WGS and how much is too much data.


Contents:

  • Introductions: 00:00-02:20
  • Gauging public perceptions of routine WGS 02:20-05:40
  • The role of industry in improving WGS accessibility and capabilities: 05:40-07:35
  • The appropriate use of pre-symptomatic and predictive risk findings: 08:00-11:15
  • Debating the discovery of untreatable diseases: 11:15-12:45
  • The impact of data biases in gene sequencing and the lack of gene references for different populations: 12:45-14:45
  • The impact of religion and lifestyle on ethical considerations in the use of WGS data: 14:45-16:00
  • Dealing with unintended findings or results that impact relatives: 16:00-16:45
  • The value of WGS in pharmacogenomic variant findings and challenging the ACMG59 list: 16:45-19:20
  • Striking the balance between fully utilizing WGS for all potential findings and ensuring maximum participation for all groups: 19:20-22:45
  • Filtering data to avoid exclusion: 22:45-24:10
  • Who owns WGS data? 24:10-25:15
  • Consent conversations: 25:15-26:30
  • Final comments: 26:30-27:15

More Episodes

9/21/2021

The evolution of PCR: From q to dd and beyond

Season 2, Ep. 16
PCR has evolved rapidly over the last few years, an evolution that has been dramatically accelerated by the COVID-19 pandemic. New technologies and approaches have been brought to the fore and the full range of applications for which this technique can be applied have been highlighted, from diagnostics to basic disease research and immunology.This episode explores this evolution, looking at how challenges presented by the pandemic forced the hand of researchers to think outside the box and build on lesser-known PCR technologies. Here, Eddy van Collenburg, Market Development Specialistat Bio-Rad (CA, USA), provides his insight into how ddPCR rose to prevalence during this time and explains how the technology is being used to enable trade, detect new variants and is being used outside of the pandemic.Discover the key role that ddPCR can play in gene therapy research, liquid biopsies, cancer research, single-cell studies and more, in this fascinating overview of the development of PCR and where the technique can go in the future.Contents:Introduction: 00:00-01:30Why was qPCR established as the gold standard for detection?01:30-03:40Limitations of qPCR during the pandemic: 03:40-05:05New varieties of PCR for faster results: 05:05-05:40New varieties for more accurate results: 05:40-06:45ddPCR working principle and advantages: 06:45-09:00Nonclinical ddPCR applications for COVID-19: 09:00-10:45ddPCR in variant detection: 10:45-12:05ddPCR in gene therapy research: 11:05-12:30Liquid biopsy and cancer research: 12:30-15:20Combining ddPCR with NGS in research: 15:20-16:15What are some of the applications of ddPCR that you find most exciting? 16:15-17:10Applications of ddPCR in single-cell studies: 17:10-21:00Improvements in ddPCR: 21:00-21:45Tips for best practice when using ddPCR: 21:45-22:50What would you ask for to improve ddPCR? 21:50-24:20
8/27/2021

Molecular therapeutics: how far have we come and what's on the horizon?

Season 2, Ep. 14
Uncover the history of molecular therapeutics, the staggering current applications and developments of these therapeutics and what their future could hold, in this episode of Talking Techniques.To explore the field of molecular therapeutics and provide an insight into their production, is Aaron Clauson, Product Manager at Zymo research. First, we cover the ins and outs of targeting the therapies and how to select the correct type of molecular therapeutic to begin developing a drug for a specific disease, before looking at some of the setbacks and safety errors that have occurred during the development of molecular therapeutics and how researchers have learned from these tragic events.Aaron also highlights the vital role of plasmids in almost all molecular therapeutic development, detailing the importance of keeping plasmid solutions and transfections free of endotoxins, revealing key solutions for avoiding these contaminants.Listen today to get all you need to know about molecular therapeutics, from their inception to their most exciting examples and how we can better communicate their benefits to the public in order to avoid mistrust and confusion - as has occurred during the COVID-19 pandemic.Contents:What counts as a molecular therapeutic? 01:45-02:40Well known molecular therapeutics: 02:40-05:00What can molecular therapeutics achieve that synthetic chemicals can’t? 05:00-05:55Targeting molecular therapeutics and picking the right type of therapeutic: 05:55-08:25Selecting the appropriate molecular therapeutic: 08:35-11:00Setbacks and safety concerns in gene therapies: 11:00-15:45Preventing off-target effects in gene therapies: 15:45-17:35Challenges in the development of molecular therapeutics: 17:35-19:05Plasmids in molecular therapeutic development: 19:05-23:55Avoiding endotoxins: 23:55-27:45What fields do you find most exciting? 27:45-28:50Better communication of gene therapies to the public: 28:50-32:00 Improving molecular therapeutic development: 32:00-37:10
8/17/2021

Adeno-associated viral therapies: harnessing the power of HPLC

Season 2, Ep. 13
This episode centers on the critical role that high-performance liquid chromatography (HPLC) plays in the production of adeno-associated viral (AAV) therapies, the latest advances in AAV design and the next steps in their development.Filling me in on all things HPLC and AAVs is Bella Neufeld, Director of R&D at Teknova. Bella reveals the essential validation and quality control steps required for the production of successful and safe AAV therapies and the role that both HPLC and liquid chromatography–mass spectrometry (LCMS) play in these steps. We also explore the latest development targets for these therapies, looking at how AAVs can be targeted to specific sites and tissues before descending into the treacherous topic of reproducibility in the field.Listen today to find out the latest tips for best practice when working with HPLC, LCMS the advantages of LCMS over other analytical techniques to assess empty and full capsids and the key principles of AAV production!ContentsIntro: 00:00-01:25Explaining HPLC and its benefits: 01:25-03:30Developing adeno-associated viruses: 03:30-05:25Chromatography in validation vs production of AAVs: 05:25-06:15Quality control vs hands on time: 06:15-07:35Challenges in AAV production: 07:35-08:55Examining the level of empty and full capsids: 08:55-10:00The role of LCMS in determining and validating AAV contents: 10:00-11:30Tips for best practice when using HPLC: 12:30-13:10The future of HPLC: 13:10-14:20Latest advances in AAV development: 14:20-15:50Targeting AAVs: 15:50-17:20Reproducibility issues in AAV development: 17:20-19:35Outro: 19:35-21:10